| Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy N Perera, S Baidya, N Weber, K Mudie, J Butler, C Curley, A Henden, ... Transfusion 64 (4), 762-765, 2024 | | 2024 |
| IL-6–mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation P Zhang, P Fleming, CE Andoniou, OG Waltner, SS Bhise, JP Martins, ... The Journal of Clinical Investigation 134 (7), 2024 | | 2024 |
| Clinical grade multiparametric cell sorting and gene-marking of regulatory T cells AP Ekwe, R Au, P Zhang, BA McEnroe, ML Tan, A Saldan, AS Henden, ... Cytotherapy, 2024 | | 2024 |
| Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia P Wong, DC Whiteman, CM Olsen, Y Yuan, J Butler, C Curley, S Durrant, ... Bone Marrow Transplantation 59 (1), 144-146, 2024 | | 2024 |
| Feasibility of prebiotic enteral nutrition provision during allogeneic stem cell transplantation S Andersen, G Kennedy, M Banks, A Henden Clinical Nutrition ESPEN 58, 426, 2023 | | 2023 |
| ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease N Hamad, I Bilmon, L Chee, A Henden, A Johnston, D Purtill, A Bajel, ... Internal Medicine Journal 53 (12), 2319-2329, 2023 | | 2023 |
| Bloodstream infections in neutropenic and non-neutropenic patients with haematological malignancies: epidemiological trends and clinical outcomes in Queensland, Australia over … AM Peri, F Edwards, A Henden, PNA Harris, MD Chatfield, DL Paterson, ... Clinical and Experimental Medicine 23 (8), 4563-4573, 2023 | 3 | 2023 |
| Fibre intake and supplementation during treatment for haematological malignancies: A scoping review S Andersen, A Henden, H Staudacher, G Kennedy, N Gavin Journal of Human Nutrition and Dietetics 36 (5), 1982-1991, 2023 | | 2023 |
| PET assessment of acute gastrointestinal graft versus host disease AP Scott, A Henden, GA Kennedy, SK Tey Bone Marrow Transplantation 58 (9), 973-979, 2023 | 1 | 2023 |
| Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2 A Henden, K Lineburg, L Le Texier, J Raju, P Crooks, E Wright, A Scott, ... Cytotherapy 25 (6), S252, 2023 | | 2023 |
| Immunotherapy: PHASE 1 CLINICAL TRIAL OF CD19 CAR-T CELLS MANUFACTURED AT THE POINT-OF-CARE CJ Hutchins, A Henderson, EC Lynam, M Abaca-Cleopas, KJ Harvey, ... Cytotherapy 25 (6), S229, 2023 | | 2023 |
| Treatment of gastrointestinal disease GR Hill, AS Henden, KH Gartlan US Patent App. 17/774,782, 2022 | | 2022 |
| Real-World Outcomes with CD19 CAR T-Cell Therapy for B-Cell Malignancies in Regional/Rural Australia: Results from the Queensland CAR T-Cell Program N Perera, AP Scott, S Hunt, C Curley, SK Tey, J Butler, AS Henden, ... Blood 140 (Supplement 1), 7500-7501, 2022 | | 2022 |
| High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following … Y Yuan, P Wong, JP Butler, A Henden, C Curley, S Durrant, H Mediwake, ... Bone Marrow Transplantation 57 (11), 1712-1715, 2022 | 1 | 2022 |
| disease. Blood. 2021; 138 (8): 722-737. AS Henden, M Koyama, RJ Robb blood 139 (22), 3347, 2022 | | 2022 |
| IFN-lambda therapy prevents severe gastrointestinal graft-versus-host disease (vol 138, pg 722, 2021) AS Henden, M Koyama, RJ Robb BLOOD 139 (22), 3346-3351, 2022 | | 2022 |
| Immunotherapy: PHASE 1 CLINICAL TRIAL OF CD19 CAR-T CELLS MANUFACTURED AT THE POINT OF CARE USING THE MILTENYI CLINIMACS PRODIGY® CJ Hutchins, A Henderson, EC Lynam, KJ Harvey, CW Leung, M Acworth, ... Cytotherapy 24 (5), S134-S135, 2022 | | 2022 |
| CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplant AC Yeh, A Varelias, A Reddy, SM Barone, SD Olver, K Chilson, ... Blood, The Journal of the American Society of Hematology 138 (26), 2874-2885, 2021 | 20 | 2021 |
| Early cytomegalovirus reactivation after allogenic bone marrow transplantation is associated with the loss of recipient-derived humoral immunity and is reduced by IL-6 inhibition P Zhang, P Fleming, C Andoniou, JP Martins, A Saldan, R Kuns, ... Blood 138, 648, 2021 | 1 | 2021 |
| IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease AS Henden, M Koyama, RJ Robb, A Forero, RD Kuns, K Chang, ... Blood, The Journal of the American Society of Hematology 138 (8), 722-737, 2021 | 22 | 2021 |
